www.onkologiecs.cz / Onkologie. 2023;17(4):224-229 / ONKOLOGIE 229 HLAVNÍ TÉMA Imunoterapie metastatického kolorektálního karcinomu LITERATURA 1. Sawicki T, Ruszkowska M, Danielewicz A, et al. Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers. 2021;13(9):2025. 2. Sinicrope FA. Increasing Incidence of Early-Onset Colorectal Cancer. N Engl J Med. 2022;386(16):1547-1558. doi: 10.1056/ NEJMra2200869. PMID: 35443109. 3. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2012;366(26):2443-2454. https://doi.org/10.1056/ NEJMoa1200690. 4. Gelsomino F, Barbolini M, Spallanzani A, et al. The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treat Rev. 2016;51:19-26. 5. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med. 2015;372(26):25092520. https://doi.org/10.1056/NEJMoa1500596. 6. O‘Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12):e0189848. doi: 10.1371/journal.pone.0189848. PMID: 29284010; PMCID: PMC5746232. 7. Kai-Keen S, Thierry A, Tae Won K, et al. KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. Journal of Clinical Oncology. 2021 39:3suppl. 6-6. 8. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: Lancet Oncol. 2017;18(9):e510. PMID: 28734759; PMCID: PMC6207072. 9. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-779. doi: 10.1200/ JCO.2017.76.9901. Epub 2018 Jan 20. PMID: 29355075. 10. Available from: https://clinicaloptions.com/CE-CME/oncology/checkmate-142:-5-yr-update/100002202-100003196. 11. André T, Van Cutsem E, Eleaz E, et al. P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW. Annals of Oncology. 2022;33:S250. 12. Eng C, Kim TW, Bendell J, et al. IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20:849-861. 13. Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34:15suppl; abstr. 3501. 14. Cousin S, Cantarel C, Guegan J-P, et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clin Cancer Res. 2021;27:2139-2147. 15. Morris VK, Parseghian CM, Escano M, et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF V600E metastatic colorectal cancer. 2022 ASCO Gastrointestinal Cancers Symposium. 2022; January 22: Abstract 12. 16. Kawazoe A, Xu R, Passhak M, et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study. Ann Oncol. 2023;34(Suppl 1):S179. doi:10.1016/j.annonc.2023.04.015. 17. Saberzadeh-Ardestani B, Jones JC, Hubbard JM, et al. Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. JAMA Netw Open. 2023;6(2):e230400. doi:10.1001/jamanetworkopen.2023.0400. 18. Antoniotti C, Rossini D, Pietrantonio F, et al. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study. Presented at ASCO Annual Meeting. 2023; Chicago: June 2-6: abstract 3500. 19. Lenz HJ, Raj Parikh A, Spigel DR, et al. Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8. Journal of Clinical Oncology. 2022;40:4_suppl, 8-8. 20. Conca V, Antoniotti C, Bergamo F, et al. Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO. Journal of Clinical Oncology. 2023;41:16_suppl.:3575-3575. 21. Folprecht G, Mende M, Liersch T, et al. Cetuximab/FOLFIRI +/- oxaliplatin or FOLFOXIRI +/- bevacizumab in patients with colorectal cancer and liver metastases (AIO CELIM2- study). J Clin Oncol. 2020;38:abstract 4024. 22. Hu H, Wang K, Huang M, et al. Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase II trial Oncologist. 2021;26:e90-e98. 23. Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1(3):207216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20. PMID: 28404093. 24. Wang F, Zhao Q, Wang Y, et al. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019;5(10):1504-1506. doi:10.1001/jamaoncol.2019.2963. 25. Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7:746-756. https:// doi.org/10.1002/cam4.1372. 26. Rousseau B, Foote MB, Maron SB, et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med. 2021;384:1168-1170. 27. WCGIC 2023, LBA-4. Available from: https://agenusbio. com/wp-content/uploads/2023/06/15Jun2023_Bullock_ ESMO-GI-Oral-Presentation_FINAL.pdf. 28. Morano F, Raimondi A, Pagani F, et al. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. J Clin Oncol. 2022;40(14):1562-1573. doi: 10.1200/JCO.21.02583. Epub 2022 Mar. 8. www.onkologiecs.cz Onkologie
RkJQdWJsaXNoZXIy NDA4Mjc=